Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Parity Group Plc LSE:PTY London Ordinary Share GB00B1235860 ORD 2P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 9.125 95,000 08:00:13
Bid Price Offer Price High Price Low Price Open Price
8.75 9.50 9.50 9.125 9.125
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Software & Computer Services 80.41 -1.06 -1.05 9
Last Trade Time Trade Type Trade Size Trade Price Currency
15:25:59 O 20,000 9.20 GBX

Parity (PTY) Latest News

More Parity News
Parity Investors    Parity Takeover Rumours

Parity (PTY) Discussions and Chat

Parity Forums and Chat

Date Time Title Posts
03/12/202011:57Parity - A New Beginning6,732
05/12/201713:53Parity - contractors working on BLOCKCHAIN tech2
31/12/201411:36Parity - 2015 the year of wearable technology11
20/3/200617:05Golden cross and renaissance for Parity10
15/9/200420:34Parity - large dump at 7p37

Add a New Thread

Parity (PTY) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
15:25:599.2020,0001,840.00O
11:21:089.2575,0006,937.50O
View all Parity trades in real-time

Parity (PTY) Top Chat Posts

DateSubject
04/12/2020
08:20
Parity Daily Update: Parity Group Plc is listed in the Software & Computer Services sector of the London Stock Exchange with ticker PTY. The last closing price for Parity was 9.13p.
Parity Group Plc has a 4 week average price of 7.03p and a 12 week average price of 7.03p.
The 1 year high share price is 10.50p while the 1 year low share price is currently 4.50p.
There are currently 101,824,020 shares in issue and the average daily traded volume is 127,076 shares. The market capitalisation of Parity Group Plc is £9,291,441.83.
11/8/2020
13:00
insideryou: Volume picked up in last few days... Always curious when that happens. But as always. Pty unloved.
08/6/2020
07:19
weatherman: Director change - no movement in price.
24/4/2020
07:02
onjohn: The Board of Parity (AIM: PTY), the data and technology focussed professional services business, announces that it has awarded Matthew Bayfield, Chief Executive Officer, 4,000,000 ordinary shares of 2 pence each in the Company ("the Share Options"). The Share Options were granted on 23 April 2020 on the recommendation of the Remuneration Committee and represent approximately 3.9% of the Company's current issued share capital. roll up and get diluted
11/2/2020
13:45
teamaccounting: Key shareholders list on PTY website has been updated, it includes Mr J S Rockliffe 2,600,000 (2.53%) not sure why < 3% is listed ?
29/1/2020
14:38
dusseldorf: ONJohn - The only thing to take this to 5p would be Helium Rising stars changing their stance, so I don't rate your chances of seeing 5p given they increased after the last trading update. Indeed, I don't think see you'll see 5p ever again as PTY will be taken out once revenues from the two strategic partnerships become evident.
29/1/2020
09:28
teamaccounting: Recruitment side is/will be affected by IR35 roll out to private sector this year, but PTY took the big hit a few years ago when it was implemented in public sector.
29/1/2020
07:50
albanyvillas: helium will go way of woodford with too much in one illiquid share - no wonder they are operating from cayman When this warns and it will. they will get scorched. Recruiters are impacted by a lack of confidence. In addition, there is continued uncertainty surrounding IR35.
15/1/2020
17:00
teamaccounting: Over 450,000 of sales and no price movement ?
09/12/2019
08:57
fillipe: Nicely up this morning. Lowest ask on show is up at the 10.50p and on a vg vol. PTY being well wanted, these days. f
13/11/2019
07:58
insideryou: Parity Group PLC HoT regarding revenue share on AI data platformSource: UK Regulatory (RNS & others)TIDMPTYRNS Number : 1793TParity Group PLC13 November 201913 November 2019AIM: PTYParity Group PLC("Parity" or "Company")Parity shares revenue with Integumen plc to deliver AI data platform solutions to clientsParity announces that it has signed Heads of Terms with Integumen plc to enter a multi-year Framework Agreement ("Agreement") to be completed on or before the 18th of December 2019. It is envisaged that the Agreement will give Parity access to Integumen's Artificial Intelligent ("AI") software which it can supply across its client base which includes the National Health Service ("NHS"), Central Government and Private Institutional clients.This Agreement accelerates Parity's transformation from a predominately commoditised recruitment business to a data consultancy service provider of intelligent data management systems, extracting value using analytics, with a focus on return on investment for our Company's 100+ institutional clients. The software includes full GDPR compliance with secure cloud data migration from existing legacy systems to a digital workplace through the military grade encryption "Drive4Growth" AI platform powered by Integumen's Rinodrive.Combined benefits:-- Recurring shared revenue streams for both Parity and Integumen in 2020 -- Value-added proposition in demand from Parity clients with c. 3 to 5-year annual contracts -- Immediate access to 100+ public and private institutional clients -- Trusted approved vendor for Government and private sectors for over 45 years -- 700+ data experts and 50+ enterprise sales and office professionals -- Existing cross-over access to educational institutional research facilities -- Access to multiple industry, public and private sector distribution routes to market -- Well defined roadmap to next level business growth for both Parity and Integumen Since the appointment of the new CEO, in February 2019, there has been structural changes to the business. Client management focus is on increasing profitability. New senior management has reduced high-volume low-margin business to low-volume high-margin multi-line business development. This includes new, higher value data expert professional service offerings. Reduction in headcount of 35% has resulted in a rolling 12-month gross cost saving of GBP2m. Heading into 2020 with these changes and with today's agreement, the board expect the Company will deliver a right-sized company with higher margins, increased profitability leading to improved shareholder value.Matthew Bayfield, CEO of Parity Group plc, comments:"Parity is pleased to be partnering with Integumen and rolling out the Drive4Growth AI platform to our client base. We have been working with many of the same clients for 45 years, so we understand their needs. With healthcare sector data in 2020 expected to double every 73 days, our clients need to securely manage and extract greater value using analytics and AI in order to make important decisions. The Drive4Growth AI platform delivers on those requirements, increases revenue per client, increases client contract term and generates a higher margin, leading to greater profitability."Gerard Brandon, CEO of Integumen plc, comments:"We are delighted to be able to roll-out the Drive4Growth AI platform in partnership with the credibility and reputation that Parity data experts hold with an extensive list of public and private institutions. We look forward to working alongside Parity to extract greater value for their clients and contribute to the transformation of the UK's National Health Service, public and private institution data over the next few years."Certain information contained in this announcement would have constituted inside information (as defined by Article 7 of Regulation (EU) No 596/2014) ("MAR") prior to its release as part of this announcement and is disclosed in accordance with the Company's obligations under Article 17 of MAR.ContactsMatthew Bayfield, CEO +44 (0) 208 543 Parity Group plc Roger Antony, GFD 5353 WH Ireland Limited Mike Coe +44 (0) 117 945 (Nominated Adviser & Broker) Chris Savidge 3470 -------------------- ----------------- +44 (0) 7836 293 Donhead Consultants (Broker) David Beck 383 -------------------- ----------------- About Parity Group: www.parity.netParity helps organisations find the right people, skills and data to support data-led business decisions. Providing advice on data and with access to qualified personnel with skills offered, either as a managed service, through resourcing in the contract or permanent market or as part of a learning and development programme.Income derives from a mix of long-term contracts with public and private sector organisations as well as expanded projects with existing clients as a result of strong relationships and a track record of high client satisfaction. Key highlights comprising of:-- Over 45 years of expertise in public and private recruitment and service contract sector -- More than 50 employees across the UK -- Client numbers exceed 100 in both UK and Ireland -- Associate numbers supporting client services exceeds 700 About Integumen: www.integumen.comIntegumen is a vertically integrated product and services company for skin related diseases, treatments and therapies with four business units:-- Labskin AI's technology platform incorporates artificial intelligence within clinical research for medical device, pharmaceuticals, cosmeceuticals and related life science test services. Labskin allows skincare, healthcare, pharmaceutical manufacturers and cosmetic companies to test their products on human-like skin in a real-world environment with full access to multiple state-of-the-art partner technologies.-- Rinodrive is a data aggregation, refining and AI analysis open-source eco-system designed to provide third-party service providers the ability to offer their clients valuable insights that support clinical, operational and financial decisions in healthcare services, third-level education, government departments and the financial sector.-- Wound pHase is developing skin and wound care products using its proprietary wound dressing technology. Working in collaboration with CBD providers creating a CBD infused diabetic wound care product range.-- Stoer-for-men skin products e-commerce division offers a range of skincare products derived from 5 natural super-ingredient plant extracts specifically for men to reduce the signs of ageing and is also used as a control for client testing within Labskin laboratories.RinoDrive "Drive4Growth": www.rinodrive.comA fully integrated set of software tools that can ingest data, in any volume, from any source in any format, interact with it, learn from it and enrich it to unlock insights and discoveries.This data management solution was developed by scientists and engineers with experience in software, sensors, AI, optofluidic research, fintech, green-tech, travel and healthcare.It was designed to allow interaction, in a cyber-secure environment, with commercially sensitive data, and to share insights across multi-disciplinary teams, generating different data formats, from multiple sources, located in different countries.RinoDrive delivers big data, AI functionality and world class infrastructure to large companies with big data problems. These include financial services, education and life science companies. Most recently completing the automation of laboratories and application of AI to unearth more knowledge about the skin microbiome. This led to the acquisition in May 2019 by Integumen PLC, to secure access to, and the exploitation of data from some of the largest cosmetic, pharmaceutical and medical companies in the world.This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.ENDAGRFFIFWEFUSEFF(END) Dow Jones NewswiresNovember 13, 2019 02:00 ET (07:00 GMT)
Parity share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
PTY
Parity
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20201204 18:17:54